By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Takeda Pharmaceutical Company has licensed from CellCentric cancer-related epigenetic target technologies for development and commercialization.

Under the agreement, Takeda's Research Group will conduct therapeutic research on molecules that will be further developed by Millenium, the biopharmaceutical firm that Takeda acquired in 2008.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Parabon NanoLabs is partnering with law enforcement to use genetic genealogy approaches to solve cold cases, Buzzfeed News reports.

A Columbia University-led team used emergency contact information from medical records to create family trees and estimate disease heritability.

NPR says a new report recommends that former research chimpanzees should be moved to retirement sanctuaries unless that move would shorten their lives.

In Science this week: ancient Southeast Asian genomes provide insight on human migration, and more.

Jun
19
Sponsored by
ACD

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.